Network-based strategies can help mono- and poly-pharmacology drug discovery: A systems biology view

Current Pharmaceutical Design

Volumn 20, Issue 8, 2014, Pages 1201-1207

  Engin, H Billur ^a   Gursoy, Attila ^a   Nussinov, Ruth ^b,c   Keskin, Ozlem ^a  

^a KOÇ UNIVERSITY   (Turkey)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Modeling; Network pharmacology; Poly pharmacology; Protein protein interaction inhibitors; Protein protein interfaces; Systems biology

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DEHYDRODIDEMNIN B; G PROTEIN COUPLED RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE INHIBITOR; TORCETRAPIB; DRUG; PROTEIN BINDING;

ARTICLE; DRUG BINDING; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG MECHANISM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SYSTEMS BIOLOGY; CHEMISTRY; DRUG DATABASE; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; PROCEDURES; PROTEIN ANALYSIS;

DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; DRUG SYNERGISM; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; SYSTEMS BIOLOGY;

EID: 84903728795     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990066     Document Type: Article

References (117)

1. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 2006; 5: 941-55.
2. O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005; 4: 1005-14.
3. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010; 31: 115-23.
4. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature 2007; 446: 975-7.
5. Cohen AA, Geva-Zatorsky N, Eden E, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008; 322: 1511-6.
6. Fliri AF, Loging WT, Volkmann RA. Cause-effect relationships in medicine: a protein network perspective. Trends Pharmacol Sci 2010; 31: 547-55.
7. Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: a future perspective. Genome Med 2009; 1: 11.
8. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drugtarget network. Nat Biotechnol 2007; 25: 1119-26.
9. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-90.
10. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Current Opinion Drug Discov Develop 2010; 13: 297-309.
11. Brown JB, Okuno Y. Systems biology and systems chemistry: new directions for drug discovery. Chem Biol 2012; 19: 23-8.
12. Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annual Rev Pharmacol Toxicol 2012; 52: 361-79.
13. Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology: official Pub Am College Neuropsychopharmacol 2009; 34: 126-41.
14. Brunton LL LJ, Parker KL. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Companies, Inc 2006.
15. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3: 301-17.
16. Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009; 14: 155-61.
17. Wanner J, Fry DC, Peng Z, Roberts J. Druggability assessment of protein-protein interfaces. Future medicinal chemistry 2011; 3: 2021-38.
18. Clackson T, Wells JA. A hot spot of binding energy in a hormonereceptor interface. Science 1995, 267: 383-6.
19. Acuner Ozbabacan SE, Gursoy A, Keskin O, Nussinov R. Conformational ensembles, signal transduction and residue hot spots: application to drug discovery. Current Opinion Drug Discov Develop 2010; 13: 527-37.
20. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450: 1001-9.
21. Thangudu RR, Bryant SH, Panchenko AR, Madej T. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J Mol Biol 2012; 415: 443-53.
22. Tuncbag N, Keskin O, Gursoy A. HotPoint: hot spot prediction server for protein interfaces. Nucleic Acids Res 2010; 38: W402-6.
23. Lise S, Archambeau C, Pontil M, Jones DT. Prediction of hot spot residues at protein-protein interfaces by combining machine learning and energy-based methods. BMC Bioinformatics 2009; 10: 365.
24. Darnell SJ, LeGault L, Mitchell JC. KFC Server: interactive forecasting of protein interaction hot spots. Nucleic Acids Res 2008; 36: W265-9.
25. Vselovsky AVA, A. I. Inhibitors of Protein-Protein Interactions as Potential Drugs. Curr Computer-Aided Drug Des 2007: 51-8.
26. Braisted AC, Oslob JD, Delano WL, et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc 2003; 125: 3714-5.
27. Vu BT, Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr Topics Microbiol Immunol 2011; 348: 151-72.
28. Canner JA, Sobo M, Ball S, et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 2009; 101: 774-81.
29. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-8.
30. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Topics Med Chem 2011; 11: 291-316.
31. Silviya D., Furdas LC, Wolfgang Sippl and Manfred Jung. Inhibition of bromodomain-mediated protein-protein interactions as a novel therapeutic strategy. Med Chem Commun 2012: 123-34.
32. Busschots K, De Rijck J, Christ F, Debyser Z. In search of small molecules blocking interactions between HIV proteins and intracellular cofactors. Mol Biosystems 2009; 5: 21-31.
33. Buchwald P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB life 2010; 62: 724-31.
34. Sperandio O, Reynes CH, Camproux AC, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 2010; 15: 220-9.
35. Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opinion Chemical Biol 2009; 13: 284-90.
36. Keskin O, Gursoy A, Ma B, Nussinov R. Principles of proteinprotein interactions: what are the preferred ways for proteins to interact? Chemical Rev 2008; 108: 1225-44.
37. Arkin MR, Randal M, DeLano WL, et al. Binding of small molecules to an adaptive protein-protein interface. Proc Nat Acad Sci USA 2003; 100: 1603-8.
38. Gao M, Skolnick J. Structural space of protein-protein interfaces is degenerate, close to complete, and highly connected. Proc Natl Acad Sci USA 2010; 107: 22517-22.
39. Eyrisch S, Helms V. Transient pockets on protein surfaces involved in protein-protein interaction. J Med Chem 2007; 50: 3457-64.
40. Eyrisch S, Helms V. What induces pocket openings on protein surface patches involved in protein-protein interactions? J Computer-Aided Molecular Des 2009; 23: 73-86.
41. Metz A, Pfleger C, Kopitz H, Pfeiffer-Marek S, Baringhaus KH, Gohlke H. Hot spots and transient pockets: predicting the determinants of small-molecule binding to a protein-protein interface. J Chemical Information Mod 2012; 52: 120-33.
42. Li X, Keskin O, Ma B, Nussinov R, Liang J. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. J Mol Biol 2004; 344: 781-95.
43. Bourgeas R, Basse MJ, Morelli X, Roche P. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PloS one 2010; 5: e9598.
44. Higueruelo AP, Schreyer A, Bickerton GR, Pitt WR, Groom CR, Blundell TL. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chemical Biol Drug Des 2009; 74: 457-67.
45. Davis FP, Sali A. The overlap of small molecule and protein binding sites within families of protein structures. PLoS Computational Biol 2010; 6: e1000668.
46. Scheiber J, Chen B, Milik M, et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis. J Chem Inf Model 2009.
47. Scheiber J, Jenkins JL, Sukuru SC, et al. Mapping adverse drug reactions in chemical space. J Med Chem 2009; 52: 3103-7.
48. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness--the Achilles heel of drug-target networks. Nature Biotechnol 2008; 26: 983-4.
49. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nature Biotechnol 2006; 24: 805-15.
50. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opinion Structural Biol 2006; 16: 127-36.
51. Hopkins AL. Network pharmacology. Nat Biotechnol 2007; 25: 1110-1.
52. Lange RP, Locher HH, Wyss PC, Then RL. The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des 2007; 13: 3140-54.
53. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-7.
54. Dixon SJ, Stockwell BR. Drug discovery: engineering drug combinations. Nat chemical Biol 2010; 6: 318-9.
55. Humeniuk R, Menon LG, Mishra PJ, et al. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Leukemia: official J the Leukemia Society of America, Leukemia Research Fund, UK 2007; 21: 2399-405.
56. Pelicano H, Carew JS, McQueen TJ, et al Targeting Hsp90 by 17- AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia: official J the Leukemia Society of America, Leukemia Research Fund, UK 2006; 20: 610-9.
57. Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004; 23: 4673-80.
58. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Annals of oncology: official J Eur Soc Med Oncol/ ESMO 2005; 16: 1667-74.
59. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biological Chem 2005; 280: 11641-7.
60. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biological Chem 2003; 278: 19245-56.
61. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009; 8: 111-28.
62. de Vries JF, Falkenburg JH, Willemze R, Barge RM. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006; 91: 912-9.
63. Xu KJ, Song J, Zhao XM. The drug cocktail network. BMC Systems Biol 2012; 6 Suppl 1: S5.
64. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Computational Biol 2011; 7: e1002323.
65. Lee JH, Kim DG, Bae TJ, et al. CDA: combinatorial drug discovery using transcriptional response modules. PloS one 2012; 7: e42573.
66. Wang YY, Xu KJ, Song J, Zhao XM. Exploring drug combinations in genetic interaction network. BMC Bioinformatics 2012; 13 Suppl 7: S7.
67. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Therapeut 2010; 9: 3137-44.
68. Keskin O, Gursoy A, Ma B, Nussinov R. Towards drugs targeting multiple proteins in a systems biology approach. Curr Topics Med Chem 2007; 7: 943-51.
69. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology--taking molecular pathology into a new dimension. Nat Rev Clinical Oncol 2009; 6: 455-64.
70. Venkatesan K, Rual JF, Vazquez A, et al. An empirical framework for binary interactome mapping. Nature Method 2009; 6: 83-90.
71. Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA 2008; 105: 6959-64.
72. Ruffner H, Bauer A, Bouwmeester T. Human protein-protein interaction networks and the value for drug discovery. Drug Discov Today 2007; 12: 709-16.
73. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008; 18: 644-52.
74. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. The Mount Sinai J medicine, New York 2007; 74: 27-32.
75. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411: 41-2.
76. Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H. Structure of protein interaction networks and their implications on drug design. PLoS Computational Biol 2009; 5: e1000550.
77. Hwang WC, Zhang A, Ramanathan M. Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin Pharmacol Therapeut 2008; 84: 563-72.
78. Kitano H. Cancer Robustness and Therapy Strategies. In cancer systems biology, bioinformatics and medicine. Springer; 2011
79. Stein A, Pache RA, Bernado P, Pons M, Aloy P. Dynamic interactions of proteins in complex networks: a more structured view. FEBS J 2009; 276: 5390-405.
80. Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Towards a molecular characterisation of pathological pathways. FEBS letters 2008; 582: 1259-65.
81. Kinnings SL, Xie L, Fung KH, Jackson RM, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 2010; 6: e1000976.
82. Dasika MS, Burgard A, Maranas CD. A computational framework for the topological analysis and targeted disruption of signal transduction networks. Biophys J 2006; 91: 382-98.
83. Lee JM, Gianchandani EP, Papin JA. Flux balance analysis in the era of metabolomics. Brief Bioinform 2006; 7: 140-50.
84. McAdams HH, Shapiro L. Circuit simulation of genetic networks. Science 1995, 269: 650-6.
85. Peleg M, Rubin D, Altman RB. Using Petri Net tools to study properties and dynamics of biological systems. J Am Med Inform Assoc 2005; 12: 181-99.
86. Li Z, Wang RS, Zhang XS, Chen L. Detecting drug targets with minimum side effects in metabolic networks. IET Syst Biol 2009; 3: 523-33.
87. Layek R, Datta A, Bittner M, Dougherty ER. Cancer therapy design based on pathway logic. Bioinformatics 2011; 27: 548-55.
88. Ruths D, Muller M, Tseng JT, Nakhleh L, Ram PT. The signaling petri net-based simulator: a non-parametric strategy for characterizing the dynamics of cell-specific signaling networks. PLoS computational Biol 2008; 4: e1000005.
89. Dasika MS, Burgard A, Maranas CD. A computational framework for the topological analysis and targeted disruption of signal transduction networks. Biophys J 2006; 91: 382-98.
90. Sridhar P, Kahveci T, Ranka S. An iterative algorithm for metabolic network-based drug target identification. Pacific Symposium on Biocomputing Pacific Symposium Biocomputing 2007: 88-99.
91. Sridhar P, Song B, Kahveci T, Ranka S. Mining metabolic networks for optimal drug targets. Pacific Symposium on Biocomputing Pacific Symposium Biocomput 2008: 291-302.
92. Yang K, Bai H, Ouyang Q, Lai L, Tang C. Finding multiple target optimal intervention in disease-related molecular network. Mol Systems Biol 2008; 4: 228.
93. Tuncbag N, Gursoy A, Nussinov R, Keskin O. Predicting proteinprotein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protocols 2011; 6: 1341-54.
94. Ogmen U, Keskin O, Aytuna AS, Nussinov R, Gursoy A. PRISM: protein interactions by structural matching. Nucleic Acids Res 2005; 33: W331-6.
95. Engin HB, Keskin O, Nussinov R, Gursoy A. A strategy based on protein-protein interface motifs may help in identifying drug offtargets. J Chem Inf Mod 2012; 52: 2273-86.
96. Xie L, Li J, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009; 5: e1000387.
97. Kar G, Keskin O, Gursoy A, Nussinov R. Allostery and population shift in drug discovery. Curr Opinion Pharmacol 2010; 10: 715-22.
98. Nussinov R, Tsai CJ, Csermely P. Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacological Sci 2011; 32: 686-93.
99. Schachter V. Protein-interaction networks: from experiments to analysis. Drug Discov Today 2002; 7: S48-54.
100. Schwikowski B, Uetz P, Fields S. A network of protein-protein interactions in yeast. Nat Biotechnol 2000; 18: 1257-61.
101. Blow N. Systems biology: Untangling the protein web. Nature 2009; 460: 415-8.
102. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011; 39: D1035-41.
103. Zhu F, Shi Z, Qin C, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012; 40: D1128-36.
104. Kuhn M, Szklarczyk D, Franceschini A, et al. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 2010; 38: D552-6.
105. BL Roth WK, Patel S, E Lopez. The Multiplicity of Serotonin Receptors: Uselessly diverse molecules or an embarrasment of riches?. Neuroscientist 2000; 6: 252-62.
106. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008; 9: 104.
107. Oprea TI, Berellini G, Olah M, Fejgin K, Boyer S. Rapid ADME Filters for Lead Discovery. In Molecular Interaction Fields. New York: Wiley-VCH; 2006 249-72
108. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Res 2007; 35: D198-201.
109. Wang R, Fang X, Lu Y, Yang CY, Wang S. The PDBbind database: methodologies and updates. J Med Chem 2005; 48: 4111-9.
110. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34: D354-7.
111. Bolton E WY, Thiessen PA, Bryant SH. PubChem: Integrated Platform of Small Molecules and Biological Activities. In Annual Reports in Computational Chemistry. Volume 4. Washington, DC: American Chemical Society; 2008
112. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers Med 2011; 5: 795-806.
113. Ji ZL, Han LY, Yap CW, Sun LZ, Chen X, Chen YZ. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug safety: an Int J Med Toxicol Drug Experience 2003; 26: 685-90.
114. Hecker N, Ahmed J, von Eichborn J, et al. SuperTarget goes quantitative: update on drug-target interactions. Nucleic acids research 2012; 40: D1113-7.
115. von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drugrepositioning. Nucleic Acids Res 2011; 39: D1060-6.
116. Davis AP, King BL, Mockus S, et al. The Comparative Toxicogenomics Database: update 2011. Nucleic Acids Res 2011; 39: D1067-72.
117. Meslamani J, Rognan D, Kellenberger E. sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins. Bioinformatics 2011; 27: 1324-6.